Edition:
United States

PledPharma AB (publ) (PLED.ST)

PLED.ST on Stockholm Stock Exchange

10.20SEK
26 May 2017
Change (% chg)

0.10kr (+0.99%)
Prev Close
10.10kr
Open
10.10kr
Day's High
10.40kr
Day's Low
10.10kr
Volume
29,275
Avg. Vol
102,413
52-wk High
50.75kr
52-wk Low
9.40kr

Latest Key Developments (Source: Significant Developments)

PledPharma gets advice from FDA for continued development of PledOx
Tuesday, 2 May 2017 02:13am EDT 

May 2 (Reuters) - PLEDPHARMA AB (PUBL) :PLEDPHARMA RECEIVES ADVICE FROM THE FDA FOR THE CONTINUED DEVELOPMENT OF PLEDOX®.  Full Article

Pledpharma Q1 net loss widens to SEK 12.3 million
Tuesday, 25 Apr 2017 02:00am EDT 

April 25 (Reuters) - PLEDPHARMA AB (PUBL) :Q1 NET LOSS SEK 12.3 MILLION VERSUS LOSS SEK 6.8 MILLION YEAR AGO.  Full Article

Pledpharma appoints Nicklas Westerholm as new CEO
Thursday, 6 Apr 2017 02:07am EDT 

PLEDPHARMA AB (PUBL) : PLEDPHARMA APPOINTS NICKLAS WESTERHOLM AS NEW CEO .NICKLAS WESTERHOLM HAS BEEN APPOINTED AS NEW CHIEF EXECUTIVE OFFICER, EFFECTIVE JUNE 16.  Full Article

Pledpharma Q4 net loss widens to SEK 11.5 million
Friday, 24 Feb 2017 02:00am EST 

Pledpharma AB (publ) :Q4 net loss 11.5 million Swedish crowns ($1.3 million) versus loss 8.8 million crowns year ago.  Full Article

Pledpharma: 8,755,570 shares subscribed for as the result of rights issue
Friday, 2 Dec 2016 01:30am EST 

PledPharma AB (publ) : Says 8,755,570 shares, representing about 43.2 percent of offered shares, were subscribed for by exercise of subscription rights . Applications for subscription without subscription rights of 42,759 shares have been received . Will receive proceeds amounting to approximately 406 million Swedish crowns ($44 million) before transaction related costs .Share capital increases by approximately 1,067,252 crowns from 1,494,152 crowns to 2,561,404 crowns.  Full Article

PledPharma Q2 net loss widens to SEK 12.0 million
Thursday, 25 Aug 2016 02:30am EDT 

PledPharma publ AB :Q2 net loss 12.0 million Swedish crowns ($1.4 million) versus loss 11.4 million crowns year ago.  Full Article

PledPharma says New data shows Pledox reduces chemotherapy-induced peripheral neuropathy by 75 pct
Tuesday, 1 Dec 2015 02:30am EST 

PledPharma publ AB:Presents new in-depth follow-up data from pliant study - Pledox shown to reduce chemotherapy-induced peripheral neuropathy by 75 percent.Data show that 24 weeks after completion of treatment Pledox reduces incidence and intensity of chemotherapy induced neuropathy by 75 pct compared with placebo.Long-term data now being presented are based on patients' own assessments of symptoms.  Full Article

More From Around the Web

BRIEF-PledPharma gets advice from FDA for continued development of PledOx

* PLEDPHARMA RECEIVES ADVICE FROM THE FDA FOR THE CONTINUED DEVELOPMENT OF PLEDOX® Source text for Eikon: Further company coverage: (Gdynia Newsroom)